BioStem Technologies has been granted four new U.S. design patents related to its placental allograft technology, marking a development in the company's intellectual property.

BioStem Technologies released highlights from its first-quarter earnings call, providing key insights into the company's financial performance and strategic initiatives. The report covers important updates for investors and stakeholders.

BioStem has announced the appointment of Jodi Ungrodt to its Board of Directors, where she will serve as the new Audit Committee Chair, as confirmed by recent reports.

BioStem Technologies has announced three new appointments to its board of directors, with an uplisting to Nasdaq remaining a primary objective for the company.

BioStem Technologies held its Q4 earnings call, discussing key financial results and business developments.

BioStem Technologies has announced the pricing of a $2.5 million private placement.

BioStem has announced the appointment of Jodi Ungrodt to its Board of Directors, where she will serve as the new Audit Committee Chair.